Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.

Download CSV

2.2M

Short interest

settlement 2026-10-30

2.7

Days to cover

-0.5 days vs prior

45.9%

Short share of volume

2026-11-18

61

Fails to deliver

settlement 2026-10-29

Fri 29 Jan

Next earnings

estimated date

-$59.2M

Insider flow, 90 days

0 buys, 93 sells

As of 2026-11-18.

Short interest

FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSON

As of 30 October 2026, short interest in REGN is 2,217,114 shares, up 66,811 shares over the last month. Over the last 48 readings it ranged from 1,785,884 shares (15 November 2024) to 3,501,203 shares (15 July 2026). At the reported average volume of 811K shares a day that is 2.7 days to cover.

Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/regn" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
PreviewDark previewAdd ?theme=dark to the src for a dark chart.
SettlementShares shortChangeAvg daily volumeDays to cover
2026-10-302,217,114+3.9%810,8502.73
2026-10-152,134,934-0.7%670,7143.18
2026-09-302,150,303-14.9%863,8422.49
2026-09-152,526,446-1.0%571,2714.42
2026-08-312,552,029+6.5%662,8643.85
2026-08-142,396,152-29.2%760,6543.15
2026-07-313,385,841-3.3%858,6623.94
2026-07-153,501,203+0.2%741,2244.72
2026-06-303,494,420+5.8%1,199,8402.91
2026-06-153,304,329+10.1%968,6903.41
2026-05-293,001,968+8.0%1,532,4321.96
2026-05-152,780,809-15.0%764,0413.64
2026-04-303,270,341+15.1%805,1124.06
2026-04-152,841,780+11.5%651,9084.36
2026-03-312,548,311+4.0%604,0794.22
2026-03-132,451,498+7.2%586,5464.18
2026-02-272,286,750+11.4%606,0733.77
2026-02-132,051,997-5.7%823,6032.49
2026-01-302,176,530-4.9%929,6772.34
2026-01-152,289,214-7.8%894,4212.56
2025-12-312,484,091-9.3%753,1963.30
2025-12-152,738,113-13.0%974,7122.81
2025-11-283,148,430+10.7%1,292,8032.44
2025-11-142,844,265+1.8%960,9532.96
2025-10-312,793,459-4.6%1,014,9142.75
2025-10-152,927,169+6.0%1,188,6762.46
2025-09-302,760,203-7.5%1,168,6772.36
2025-09-152,985,318+5.6%960,7523.11
2025-08-292,827,689+20.4%959,1242.95
2025-08-152,349,138+2.5%1,061,9432.21
2025-07-312,291,886+10.5%920,2782.49
2025-07-152,074,491-7.9%843,4552.46
2025-06-302,252,720+10.9%1,145,6971.97
2025-06-132,031,432-24.7%1,604,7361.27
2025-05-302,697,824-3.6%1,415,4301.91
2025-05-152,798,186-3.1%1,513,2831.85
2025-04-302,887,463+11.0%1,200,3472.41
2025-04-152,601,922-6.8%1,222,3722.13
2025-03-312,790,935-14.1%948,9272.94
2025-03-143,249,157+26.6%1,030,9843.15
2025-02-282,565,723+16.4%778,8433.29
2025-02-142,204,900+0.8%1,068,8242.06
2025-01-312,187,734+3.3%913,4242.40
2025-01-152,117,354+1.0%834,7752.54
2024-12-312,095,552+11.5%852,5462.46
2024-12-131,879,771+4.5%849,6152.21
2024-11-291,799,097+0.7%838,0832.15
2024-11-151,785,884-3.6%817,3132.19

Daily short volume

FINRA Reg SHO, the last 30 sessions. JSON

As of 18 November 2026, the short share of REGN volume is 45.9%, down 7.9 points over the last five sessions. Over the last 30 readings it ranged from 27.5% (4 November 2026) to 60.7% (20 October 2026). The latest reading is in line with the 30-session average of 46.5%, on 331K shares reported.

DateShort volumeTotal volumeShort shareExempt
2026-11-18152K331K45.9%1,984
2026-11-17127K257K49.6%7,525
2026-11-1688K251K35.1%7,088
2026-11-13106K249K42.5%7,697
2026-11-12218K457K47.8%9,906
2026-11-11253K469K53.9%13,275
2026-11-1067K179K37.4%1,495
2026-11-09115K294K39.1%7,842
2026-11-06104K301K34.4%7,270
2026-11-05240K626K38.3%8,736
2026-11-04157K572K27.5%19,137
2026-11-03259K489K53.0%59,518
2026-11-02436K787K55.3%206,801
2026-10-30597K1.2M48.8%171,914
2026-10-29173K295K58.6%4,764
2026-10-2882K143K57.4%1,844
2026-10-2789K221K40.1%1,411
2026-10-2657K148K38.5%601
2026-10-2365K150K43.5%435
2026-10-22189K325K58.1%7,951
2026-10-21124K211K58.7%1,687
2026-10-20130K214K60.7%3,870
2026-10-1997K170K57.0%292
2026-10-1692K227K40.7%684
2026-10-15147K294K50.0%4,332
2026-10-14150K317K47.5%1,455
2026-10-1391K216K42.0%598
2026-10-12103K261K39.2%1,866
2026-10-0989K191K46.7%1,306
2026-10-08106K225K47.3%447

Fails to deliver

SEC, the last 30 settlement dates with a fail. JSON

As of 29 October 2026, the fails-to-deliver balance in REGN is 61 shares, up 9 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (11 May 2026) to 2,016 shares (18 August 2026). The latest reading sits at the bottom of that range.

SettlementShares failedPriceValue
2026-10-2961$813.27$50K
2026-10-2752$807.67$42K
2026-10-236$819.09$5K
2026-10-2212$805.67$10K
2026-10-1674$796.34$59K
2026-10-158$778.36$6K
2026-09-178$774.61$6K
2026-09-09341$810.31$276K
2026-09-031,556$852.03$1.3M
2026-08-2021$840.84$18K
2026-08-182,016$805.93$1.6M
2026-08-1460$805.97$48K
2026-08-101,444$784.36$1.1M
2026-08-03132$762.63$101K
2026-07-311,276$738.34$942K
2026-07-301$695.42$695
2026-07-2428$651.91$18K
2026-07-2328$651.18$18K
2026-07-2228$675.19$19K
2026-07-2052$676.69$35K
2026-06-309$631.81$6K
2026-06-2956$632.90$35K
2026-06-2219$609.94$12K
2026-06-111$601.65$602
2026-06-04325$618.95$201K
2026-05-26662$638.88$423K
2026-05-18160$698.25$112K
2026-05-131,542$723.41$1.1M
2026-05-111$714.89$715
2026-05-07151$721.05$109K

Insider trades

SEC Form 4, newest first. JSON

Insiders at REGN reported 93 open-market sells worth $59.2M in the last 90 days and no open-market buys. Latest filing: SING GEORGE L (Director) on 2026-11-17.

DateInsiderTitleTypeSharesPriceValueOwned after
2026-11-17SING GEORGE LDirectorSell465$958.11$446K23K
2026-11-17SING GEORGE LDirectorSell359$957.49$344K24K
2026-11-17SING GEORGE LDirectorSell176$956.96$168K24K
2026-11-17MURPHY ANDREW JCo-Chief Scientific OfficerSell340$964.36$328K47K
2026-11-17MURPHY ANDREW JCo-Chief Scientific OfficerSell255$963.60$246K47K
2026-11-17MURPHY ANDREW JCo-Chief Scientific OfficerSell295$962.70$284K47K
2026-11-17MURPHY ANDREW JCo-Chief Scientific OfficerSell584$961.45$561K48K
2026-11-17MURPHY ANDREW JCo-Chief Scientific OfficerSell257$960.65$247K48K
2026-11-17MURPHY ANDREW JCo-Chief Scientific OfficerSell506$959.45$485K49K
2026-11-17MURPHY ANDREW JCo-Chief Scientific OfficerSell244$958.27$234K49K
2026-11-17MURPHY ANDREW JCo-Chief Scientific OfficerSell202$957.53$193K49K
2026-11-17MURPHY ANDREW JCo-Chief Scientific OfficerSell346$956.70$331K49K
2026-11-17MURPHY ANDREW JCo-Chief Scientific OfficerSell313$955.48$299K50K
2026-11-17MURPHY ANDREW JCo-Chief Scientific OfficerSell313$954.45$299K50K
2026-11-17MURPHY ANDREW JCo-Chief Scientific OfficerSell671$953.69$640K50K
2026-11-17MURPHY ANDREW JCo-Chief Scientific OfficerSell220$952.75$210K51K
2026-11-17MURPHY ANDREW JCo-Chief Scientific OfficerSell298$951.75$284K51K
2026-11-17MURPHY ANDREW JCo-Chief Scientific OfficerSell74$950.61$70K52K
2026-11-17MURPHY ANDREW JCo-Chief Scientific OfficerSell93$949.69$88K52K
2026-11-16SING GEORGE LDirectorSell1K$960.26$960K24K
2026-11-16McCourt MarionEVP CommercialSell26$971.93$25K10K
2026-11-16McCourt MarionEVP CommercialSell63$965.62$61K10K
2026-11-16McCourt MarionEVP CommercialSell21$964.69$20K10K
2026-11-16McCourt MarionEVP CommercialSell42$963.70$40K10K
2026-11-16McCourt MarionEVP CommercialSell41$962.44$39K10K
2026-11-16McCourt MarionEVP CommercialSell59$961.36$57K10K
2026-11-16McCourt MarionEVP CommercialSell49$960.31$47K11K
2026-11-16McCourt MarionEVP CommercialSell66$959.46$63K11K
2026-11-16McCourt MarionEVP CommercialSell44$958.47$42K11K
2026-11-16McCourt MarionEVP CommercialSell22$956.01$21K11K
2026-11-16McCourt MarionEVP CommercialSell30$955.51$29K11K
2026-11-16McCourt MarionEVP CommercialSell59$954.46$56K11K
2026-11-16McCourt MarionEVP CommercialSell44$952.79$42K11K
2026-11-16MURPHY ANDREW JCo-Chief Scientific OfficerTax withholding12K$960.02$11.5M52K
2026-11-16MURPHY ANDREW JCo-Chief Scientific OfficerExercise or conversion17K$381.92$6.5M64K
2026-11-04Pitofsky JasonSVP ControllerSell179$950.76$170K0
2026-11-04Pitofsky JasonSVP ControllerSell35$945.61$33K4K
2026-11-04Pitofsky JasonSVP ControllerSell108$944.22$102K4K
2026-11-04Pitofsky JasonSVP ControllerSell529$943.53$499K4K
2026-11-04Pitofsky JasonSVP ControllerSell1K$942.31$1.1M5K
2026-11-04Pitofsky JasonSVP ControllerSell982$941.58$925K6K
2026-11-04Pitofsky JasonSVP ControllerSell575$940.46$541K7K
2026-11-04Pitofsky JasonSVP ControllerSell439$939.57$412K8K
2026-11-04Pitofsky JasonSVP ControllerExercise or conversion905$492.00$445K8K
2026-11-04Pitofsky JasonSVP ControllerExercise or conversion1K$644.54$953K7K
2026-11-04Pitofsky JasonSVP ControllerExercise or conversion2K$726.53$1.1M6K
2026-11-03Zoghbi Huda YDirectorSell500$971.06$486K2K
2026-11-03Zoghbi Huda YDirectorSell7K$970.42$6.7M2K
2026-11-03Zoghbi Huda YDirectorExercise or conversion7K$380.95$2.8M9K
2026-11-03MURPHY ANDREW JCo-Chief Scientific OfficerGift1K$0.00$047K
2026-11-02SING GEORGE LDirectorSell200$970.18$194K25K
2026-11-02SING GEORGE LDirectorSell1K$967.07$1.0M25K
2026-11-02SING GEORGE LDirectorSell2K$966.27$1.5M26K
2026-11-02SING GEORGE LDirectorSell7K$965.38$6.8M28K
2026-11-02SING GEORGE LDirectorSell3K$964.57$2.6M35K
2026-11-02SING GEORGE LDirectorSell4K$963.47$4.2M38K
2026-11-02SING GEORGE LDirectorSell3K$962.61$2.4M42K
2026-11-02SING GEORGE LDirectorSell540$961.85$519K45K
2026-11-02SING GEORGE LDirectorSell1K$960.57$1.2M45K
2026-11-02SING GEORGE LDirectorExercise or conversion7K$380.95$2.8M46K
2026-11-02SING GEORGE LDirectorExercise or conversion8K$376.69$2.9M39K
2026-11-02POON CHRISTINE ADirectorSell201$971.31$195K5K
2026-11-02POON CHRISTINE ADirectorSell937$970.51$909K5K
2026-11-02POON CHRISTINE ADirectorSell3K$969.50$3.1M6K
2026-11-02POON CHRISTINE ADirectorSell2K$968.58$2.4M10K
2026-11-02POON CHRISTINE ADirectorSell772$967.38$747K12K
2026-11-02POON CHRISTINE ADirectorSell218$966.74$211K13K
2026-11-02POON CHRISTINE ADirectorExercise or conversion8K$376.69$2.9M13K
2026-11-02LAROSA JOSEPH JEVP General Counsel and SecretSell527$966.11$509K39K
2026-11-02LAROSA JOSEPH JEVP General Counsel and SecretSell4K$965.41$3.8M39K
2026-11-02LAROSA JOSEPH JEVP General Counsel and SecretTax withholding9K$950.50$8.3M43K
2026-11-02LAROSA JOSEPH JEVP General Counsel and SecretExercise or conversion12K$381.92$4.7M52K
2026-11-02Fenimore Christopher R.EVP Finance CFOGift15$0.00$022K
2026-11-02Fenimore Christopher R.EVP Finance CFOTax withholding4K$950.50$4.0M22K
2026-11-02Fenimore Christopher R.EVP Finance CFOExercise or conversion6K$381.92$2.3M26K
2026-10-30McCourt MarionEVP CommercialSell1K$869.43$984K11K
2026-10-30Guarini KathrynDirectorSell400$900.00$360K603
2026-10-30Guarini KathrynDirectorExercise or conversion400$719.37$288K1K
2026-10-30BROWN MICHAEL SDirectorSell2K$875.00$1.7M1K
2026-10-30BROWN MICHAEL SDirectorExercise or conversion2K$725.89$1.4M3K
2026-10-14MURPHY ANDREW JCo-Chief Scientific OfficerSell50$781.47$39K48K
2026-10-14MURPHY ANDREW JCo-Chief Scientific OfficerSell463$780.63$361K48K
2026-10-14MURPHY ANDREW JCo-Chief Scientific OfficerSell380$779.59$296K48K
2026-10-14MURPHY ANDREW JCo-Chief Scientific OfficerSell454$778.64$354K49K
2026-10-14MURPHY ANDREW JCo-Chief Scientific OfficerSell38$777.76$30K49K
2026-10-14MURPHY ANDREW JCo-Chief Scientific OfficerSell66$776.31$51K49K
2026-10-14MURPHY ANDREW JCo-Chief Scientific OfficerSell376$775.46$292K49K
2026-10-14MURPHY ANDREW JCo-Chief Scientific OfficerSell121$774.48$94K50K
2026-10-14MURPHY ANDREW JCo-Chief Scientific OfficerSell224$773.40$173K50K
2026-10-14MURPHY ANDREW JCo-Chief Scientific OfficerSell211$772.56$163K50K
2026-10-14MURPHY ANDREW JCo-Chief Scientific OfficerSell283$771.56$218K50K
2026-10-14MURPHY ANDREW JCo-Chief Scientific OfficerSell12$770.20$9K50K
2026-10-14MURPHY ANDREW JCo-Chief Scientific OfficerSell127$769.30$98K51K
2026-10-14MURPHY ANDREW JCo-Chief Scientific OfficerSell105$768.33$81K51K
2026-10-14MURPHY ANDREW JCo-Chief Scientific OfficerSell192$767.39$147K51K
2026-10-14MURPHY ANDREW JCo-Chief Scientific OfficerSell279$766.47$214K51K
2026-10-14MURPHY ANDREW JCo-Chief Scientific OfficerSell271$765.39$207K51K
2026-10-14MURPHY ANDREW JCo-Chief Scientific OfficerSell219$764.40$167K51K
2026-10-14MURPHY ANDREW JCo-Chief Scientific OfficerSell25$763.76$19K52K
2026-10-14MURPHY ANDREW JCo-Chief Scientific OfficerSell55$762.57$42K52K

Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.

Planned sales (Form 144)

Newest first. JSON

23 Form 144 notices on file for REGN worth $57.6M at the prices reported; 15 in the last 90 days worth $51.4M. Latest: MURPHY ANDREW J filed on 2026-11-17 to sell 5,011 shares ($4.8M) from 2026-11-17.

FiledSellerSharesMarket valueOf outstandingSale fromBroker
2026-11-17MURPHY ANDREW JOfficer5K$4.8M0.005%2026-11-17UBS Financial Services, Inc.
2026-11-17GEORGE L. SINGDirector1K$958K0.001%2026-11-17Morgan Stanley Smith Barney LLC Executive Financial Services
2026-11-16GEORGE L. SINGDirector1K$960K0.001%2026-11-16Morgan Stanley Smith Barney LLC Executive Financial Services
2026-11-16McCourt MarionOfficer566$545K0.001%2026-11-16UBS Financial Services Inc.
2026-11-04Jason PitofskyOfficer4K$3.8M0.004%2026-11-04UBS Financial Services Inc
2026-11-03Huda ZoghbiDirector7K$7.2M0.007%2026-11-03UBS Financial Services Inc
2026-11-02Joseph LaRosaOfficer4K$4.3M0.004%2026-11-02UBS Financial Services Inc
2026-11-02GEORGE L. SINGDirector21K$20.4M0.021%2026-11-02Morgan Stanley Smith Barney LLC Executive Financial Services
2026-10-30McCourt MarionOfficer1K$984K0.001%2026-10-30UBS Financial Services Inc.
2026-10-30Guarini KathrynDirector400$360K0.000%2026-10-30UBS Financial Services, Inc.
2026-10-30MICHAEL S BROWNDirector2K$1.6M0.002%2026-10-30Morgan Stanley Smith Barney LLC Executive Financial Services
2026-10-14MURPHY ANDREW JOfficer4K$3.2M0.004%2026-10-14UBS Financial Services, Inc.
2026-09-03McCourt MarionOfficer1K$969K0.001%2026-09-03UBS Financial Services Inc.
2026-09-02McCourt MarionOfficer1K$1.0M0.001%2026-09-02UBS Financial Services Inc.
2026-09-02Guarini KathrynDirector400$340K0.000%2026-09-02UBS Financial Services, Inc.
2026-08-10Zoghbi Huda YDirector800$640K0.001%2026-08-10UBS Financial Services, Inc.
2026-08-10Guarini KathrynBoard member400$320K0.000%2026-08-10UBS Financial Services, Inc.
2026-02-19Zoghbi Huda YDirector2K$1.3M0.002%2026-02-19UBS Financial Services, Inc.
2026-02-09Arthur F. RyanDirector400$314K0.000%2026-02-09J.P. Morgan Securities LLC
2026-02-09Pitofsky JasonOfficer2K$1.6M0.002%2026-02-09UBS Financial Services, Inc.
2026-01-07Bassler Bonnie LDirector2K$1.2M0.001%2026-01-07RBC CAPITAL MARKETS LLC
2025-11-20Bassler Bonnie LDirector760$570K0.001%2025-11-20RBC CAPITAL MARKETS LLC
2025-11-07Jason PitofskyOfficer431$281K0.000%2025-11-07UBS Financial Services Inc

Large holders (13D and 13G)

One row per reporting person with its latest filing, newest first. JSON

1 holder reports 5% or more of REGN in its latest filing, on Schedule 13G (passive). The holder is Vanguard Capital Management at 7.4% of the class (7,660,810 shares), filed 2026-04-30 for an event on 2026-03-31.

FiledFormHolderSharesOf classEvent
2026-04-3013GVanguard Capital Managementinvestment adviser7.7M7.4%2026-03-31
2026-03-2713G/Ano. 7The Vanguard Groupinvestment adviser00.0%2026-03-13

13F holders

Tracked managers holding REGN at their latest 13F. JSON

9 of the 30 tracked managers held REGN at their latest 13F, $2.44B in total at quarter-end prices. AQR Capital Management is the largest at $978.9M (0.3% of its portfolio) as of 2026-09-30. Over the prior quarter 8 added shares and 1 cut.

FundQuarterSharesValueOf portfolioChange in shares
AQR Capital Management2026-09-301.3M$978.9M0.29%+186K
Two Sigma Investments2026-09-30870K$659.3M0.46%+213K
Citadel Advisors2026-09-30353K$267.5M0.03%+295K
Renaissance Technologies2026-09-30272K$206.4M0.28%+124K
Millennium Management2026-09-30148K$111.9M0.04%-18K
Point72 Asset Management2026-09-30124K$94.3M0.10%new
Bridgewater Associates2026-09-30106K$80.3M0.35%+55K
D. E. Shaw & Co.2026-09-3059K$44.5M0.02%+20K
Fisher Asset Management2026-09-30347$264K0.00%new

Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.

Financials

SEC XBRL, as filed. JSON

In Q3 FY 2026 (quarter ended 2026-09-30) Regeneron Pharmaceuticals reported revenue of $5.12B, up 36.3% from the same quarter a year earlier, and net income of $1.95B (18.45 diluted EPS). In FY 2025 it generated $4.98B of operating cash flow and spent $3.44B on buybacks and $370.3M on dividends. As of 2026-09-30, cash was $3.66B against $1.99B of debt.

Cash
$3.66B
Debt
$1.99B
Equity
$33.50B
Total assets
$44.41B
Shares outstanding
93,955,110

Quarterly, last 8 quarters

QuarterPeriod endRevenueNet incomeMarginDiluted EPS
Q3 FY 20262026-09-30$5.12B$1.95B38.1%18.45
Q2 FY 20262026-06-30$4.29B$1.30B30.2%12.23
Q1 FY 20262026-03-31$3.61B$727.2M20.2%6.75
Q4 FY 2025derived2025-12-31$3.88B$844.6M21.7%n/a
Q3 FY 20252025-09-30$3.75B$1.46B38.9%13.62
Q2 FY 20252025-06-30$3.68B$1.39B37.9%12.81
Q1 FY 20252025-03-31$3.03B$808.7M26.7%7.27
Q4 FY 2024derived2024-12-31$3.79B$917.7M24.2%n/a

Fiscal years, with buybacks and dividends

Fiscal yearEndsRevenueNet incomeOperating cash flowCapexBuybacksDividends
FY 20252025-12-31$14.34B$4.50B$4.98B$898.4M$3.44B$370.3M
FY 20242024-12-31$14.20B$4.41B$4.42B$755.9M$2.60B$0
FY 20232023-12-31$13.12B$3.95B$4.59B$718.6M$2.23B$0
FY 20222022-12-31$12.17B$4.34B$5.01B$590.1M$2.08Bn/a
FY 20212021-12-31$16.07B$8.08B$7.08B$551.9M$1.65Bn/a

Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-09-30; shares outstanding as of 2012-07-13 from the cover page.

What this page is

Regeneron Pharmaceuticals in the regulatory record

Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.

Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.

This page follows Regeneron Pharmaceuticals (REGN), SEC CIK 872589, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.

Source and updates

Short interest
FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-30.JSON and CSV
Daily short volume
FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-18.JSON and CSV
Fails to deliver
SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-29.JSON and CSV
Planned sales
SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-11-17.JSON and CSV
Large holders
SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-04-30.JSON and CSV
13F holders
SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-09-30.JSON and CSV
Financials
SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-09-30.JSON and CSV
Earnings dates
SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-10-30.JSON and CSV
Insider trades
SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-11-17.JSON and CSV
Company record
EDGAR filing index for CIK 872589Ticker, name and exchange from the SEC's company list, refreshed weekly.
Rate limits
10 requests a minute without a key, 30 with a free key from a free account.

How to read it

  • Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
  • Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
  • Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.

Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.

Datasets

Frequently Asked Questions

How much of REGN is sold short?
2,217,114 shares were held short at the 2026-10-30 settlement, 2.7 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is REGN's daily short volume?
On 2026-11-18, 151,920 of the 330,804 REGN shares reported to FINRA were sold short, 45.9% of the day's reported volume. Short volume is a flow for one day, not a position.
Does REGN have fails to deliver?
The SEC's latest file shows 61 REGN shares failed to deliver at settlement 2026-10-29. Fails are reported per settlement date and published twice a month with a lag.
Are REGN insiders buying or selling?
Insiders at REGN reported 93 open-market sells worth $59.2M in the last 90 days and no open-market buys. Latest filing: SING GEORGE L (Director) on 2026-11-17.
Have REGN insiders filed to sell?
23 Form 144 notices on file for REGN worth $57.6M at the prices reported; 15 in the last 90 days worth $51.4M. Latest: MURPHY ANDREW J filed on 2026-11-17 to sell 5,011 shares ($4.8M) from 2026-11-17.
Who owns 5% or more of REGN?
1 holder reports 5% or more of REGN in its latest filing, on Schedule 13G (passive). The holder is Vanguard Capital Management at 7.4% of the class (7,660,810 shares), filed 2026-04-30 for an event on 2026-03-31.
What did REGN report last quarter?
In Q3 FY 2026 (quarter ended 2026-09-30) Regeneron Pharmaceuticals reported revenue of $5.12B, up 36.3% from the same quarter a year earlier, and net income of $1.95B (18.45 diluted EPS). In FY 2025 it generated $4.98B of operating cash flow and spent $3.44B on buybacks and $370.3M on dividends. As of 2026-09-30, cash was $3.66B against $1.99B of debt.
Which tracked 13F managers own REGN?
9 of the 30 tracked 13F managers held REGN shares at their latest filing, $2.44B in all. The largest: Cliff Asness's AQR Capital Management (1.3M shares, $978.9M), Two Sigma Investments (870K shares, $659.3M), Ken Griffin's Citadel Advisors (353K shares, $267.5M), Renaissance Technologies (272K shares, $206.4M), Izzy Englander's Millennium Management (148K shares, $111.9M), Steve Cohen's Point72 Asset Management (124K shares, $94.3M). The table above lists all 9.

Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.